MoleMate cancer tester 'less accurate' than doctors' eyes

July 24, 2012

(Medical Xpress) -- Differentiating melanomas from other pigmented skin lesions in primary care is challenging - but a device used by Australian and British doctors to determine whether a patient has a melanoma has been found to be less accurate than GPs using their eyes and judgment, according to a researcher at The University of Western Australia. 

In fact, MoleMate does not improve the diagnosis of but results in more patients with benign being referred for investigation and treatment, according to Winthrop Professor Jon Emery, Chair of General Practice and Head of the School of Primary Aboriginal and Rural Health Care. Professor Emery, who also holds an adjunct position as Senior Clinical Research Associate at Cambridge University in the UK, works on cancer diagnosis and management in primary care, genetic medicine and the conduct of complex interventions trials.

Professor Emery is co-author of a study of the MoleMate system which looked at almost 1300 patients in 15 practices. "Worldwide, the incidence of melanoma is increasing faster than any other cancer, with an approximate doubling of rates every 10 to 20 years in countries with white populations," Professor Emery said.

"In Britain, for example, the incidence of melanoma has quadrupled over the past 40 years. Early detection is critical in reducing mortality and morbidity from melanoma, as the stage 1 disease has five-year survival rates of more than 95 per cent compared with 10-20 per cent for stage 4 of the disease. As pigmented lesions are commonly seen in primary care consultations, GPs need to be able to reassure people with benign lesions and rapidly refer those with suspicious lesions."

Published in the British Medical Journal, the study found that GPs believed the device improved their diagnostic accuracy when it actually performed no better than checklists that suggest GPs look for signs such as the size, colour and shape of lesions and any inflammation, oozing or change in sensation.

"By being perceived more positively, MoleMate provided false reassurance," Professor Emery said. "In fact, the systematic application of best practice guidelines proved more accurate."

The MoleMate system is said to be easier to learn than dermoscopy and predicts melanoma based on images of the epidermal and dermal melanin and vasculature, and the collagen content of the lesion. However, the researchers found the systematic application of best-practice guidelines, including recommended checklists, was the best way to manage suspicious-looking in .

Explore further: Shave biopsy is a safe and acceptable method for initial evaluation of melanoma

More information: www.bmj.com/content/345/bmj.e4110

Related Stories

Shave biopsy is a safe and acceptable method for initial evaluation of melanoma

May 23, 2011
A shave biopsy is a reasonably safe and accurate method for the initial diagnosis of melanoma, according to a study published in the April issue of the Journal of the American College of Surgeons. In the past, some physicians ...

Melanoma screening by physicians associated with finding more cancers than patient self-detection

July 18, 2011
Physician-based screening for melanoma is associated with higher rates of physician-detected melanoma and detection of thinner melanoma, according to a report published Online First today by Archives of Dermatology, one of ...

Risk of second primary melanoma up in pediatric patients

June 28, 2012
(HealthDay) -- Pediatric patients diagnosed with an invasive cutaneous melanoma have nearly double the relative risk of developing a subsequent primary melanoma, compared with adults, according to a study published online ...

Recommended for you

Promising new treatment for rare pregnancy cancer leads to remission in patients

November 24, 2017
An immunotherapy drug can be used to cure women of a rare type of cancer arising from pregnancy when existing treatments have failed.

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.